Glivec's copy products and compulsory enforcement

As the Korean leukemia patients group continued to make their struggle for lowering the reimbursed price of Glivec after discontinuing the pricing negotiation with Novartis Korea, the Korean government's decision on the compulsory enforcement has emerged as a critical issue.

In situation where any pricing negotiation on Glivec is no longer expected, the leukemia patients are hopefully depend...